Stavudine Articles
South African state drug tender system under fire
10 November 2009
Final FDA OK for Mylan's generic Zerit
12 January 2009
UPDATE: Zimbabwe pharmacies face ARV shortages
21 January 2008
Uganda joint venture with Indian Rx firm
10 December 2007
ARVs drug plant opens in Uganda
15 October 2007
FDA gives nod to 50th and 51st PEPFAR drugs
20 August 2007
Zymes' CoQ10 reduces NRTI nerve damage
6 August 2007
Thailand and Brazil collaboration fears
28 May 2007
Ranbaxy ARVs back on WHO list
22 August 2005
US FDA "tentative OK" for Aurobindo stavudine
11 July 2005
South Africa awards ARV drug tenders
14 March 2005
Ranbaxy withdraws generic antiretrovirals on quality concerns
15 November 2004
Pharco gets compulsory license to make ARVs in Zambia
4 October 2004
Zambia set to start ARV production
27 September 2004
Three Ranbaxy ARVs taken off WHO list
16 August 2004
Cipla patents Triomune in South Africa
19 July 2004
Zimbabwe ARV import row widens
1 March 2004
Preliminary data from three-year Viread trial
16 February 2004
Zimbabwean govt accused over ARV
2 February 2004
Indian firms urge govt over life-saving drugs
5 January 2004
MSF: WHO HIV Rx price target "lacks ambition"
8 December 2003
Thailand gives Myanmar HIV/AIDS drug cocktail
13 October 2003
Cipla registers five anti-AIDS drugs in South Africa
29 September 2003
Kaletra shows long-term benefits in HIV
22 September 2003
Gilead's Emtriva shows efficacy at 60 wks
28 July 2003
Gilead Sciences set to beat expectations
21 July 2003
Poor take-up for Cipla HIV/AIDS cocktail
31 March 2003
Viramune as good as more costly Sustiva
24 February 2003
Positive Ph III data with Triangle's emtricitabine
17 February 2003
First Chinese HIV/AIDS drugs delivered
3 February 2003
China to make four HIV/ AIDS drugs from Jan
13 January 2003
Triangle's Coviracil trial "un-blinded"
5 August 2002
Switching to B-MS' atazanavir cuts lipids
22 July 2002
Thai/African HIV/AIDS generic drug deals
27 May 2002
Stock Commentary - New York
20 May 2002
WHO "essential list" of malaria, AIDS drugs
6 May 2002
Kenyan HIV/AIDS drug shortages hit patients
29 April 2002
Thailand producing AIDS triple-drug pill
1 April 2002
WHO recommends AIDS drugs, makers
1 April 2002
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
Chinese firms apply to make HIV/AIDS drugs
20 November 2001
BI reports 96-week Viramune data
30 October 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Cipla drops HIV/AIDS cocktail price in India
13 July 2001
Cipla to supply Nigeria with HIV/AIDS drugs
9 May 2001
Merck & Co, B-MS cut drug prices further
20 March 2001
MSF urges Yale over stavudine patent
15 March 2001
Drug majors cut AIDS drug prices further
7 March 2001
Cipla talks with WHO over AIDS drug offer
1 March 2001
Kenyan moves to buy cheap AIDS drugs
26 February 2001
10 countries to get Cipla's AIDS drugs
26 February 2001
Cipla talks with MNCs over HIV drug offer
13 February 2001
Warnings issued on use of B-MS' antiretrovirals in pregnancy
8 January 2001
First cheap HIV drugs for Senegal
26 October 2000
Gilead Sciences boosted on tenefovir DF resistance data
25 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
B-MS up on strong sales of Glucophage
24 July 2000
Thailand boosts locally- made HIV generics
30 June 2000
Triangle seeks to lift halt on HIV drug
13 June 2000
Abbott's ABT-378/r, efficacy in PI-resistant patients
3 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Triangle slumps on FDA request for more Coactinon data
15 December 1999
US Biosciences halts lodenosine HIV trial after death of patient
15 October 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
B-MS South Africa deal for AIDS program
7 September 1999
Sustiva cleared in Canada for HIV
29 March 1999
New trials support role of nevirapine in HIV
29 March 1999
US HIV conference data in brief
4 February 1999
Abbott's ABT-378 potent against HIV
2 February 1999
Existing Opportunities In The New HIV/AIDS Treatment Paradigm
16 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
US Bioscience Starts USA Trials Of Lodenosine In HIV Patients
17 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Abbott's ABT-378 in Phase III By Year End?
9 July 1998
First Data With USB's Lodenosine
9 July 1998
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
